Income Taxes (Tables)

12 Months Ended

Dec. 31, 2022


	December 31,
	2022		2021
Statutory Federal Tax	$	(2,438,064)	$	(5,660,216)
State and local taxes		(1,586,715)		(2,232,443)
Foreign taxes		(40,474)		(8,634)
Stock-based compensation		—		13,902
In-process R&D		—		2,533,426
Change in warrant liability		—		(305,737)
Other		(53,146)		(9,646)
Change in valuation allowance		4,118,399		5,669,348
Effective Tax Rate	$	—	$	—


	December 31,
	2022		2021
Deferred Tax Assets:
Start-up costs	$	26,091	$	28,700
Patents		395,795		419,756
Non-qualified stock options		492,463		370,532
Net operating losses		10,680,094		7,645,253
Capitalized research and development expenses		815,787		—
OCI – Unrealized foreign exchange loss		1,717		30,040
Foreign research costs		6,854		2,522
Research and development tax credit		132,147		—
Interest expense		8,977		6,832
Foreign net operating loss		159,239		126,730
Accrued bonuses		29,034
Fixed Assets		390		—
Total deferred tax assets	$	12,748,588	$	8,630,365
Deferred tax liabilities:
Fixed assets		—		(176)
Total Deferred Tax Liabilities		—		(176)
Valuation allowance		(12,748,588)		(8,630,189)
Net Deferred Tax Assets		—		—

Scopus BioPharma Inc. 10-K